The first psilocybin compound to secure two positive Phase 3 readouts in treatment-resistant depression has cleared a major development hurdle, prompting the DEA to raise its 2026 psilocybin production quota by 67%. This regulatory shift reflects growing acceptance of psychedelic-based psychiatry and sets a higher supply baseline for clinical programs.

Alto Neuroscience is highlighted as one of five companies leveraging the expanding psilocybin pathway to develop treatments for CNS disorders. With regulators increasing quotas and investors mobilizing capital, Alto joins peers in advancing novel therapies targeting neuroplasticity and depression.